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Background: The aim of this study was to test whether repeatable biomarkers collected from serum,
bronchoalveolar lavage (BAL) and sputum of healthy smokers and smokers with COPD would have a prognostic
value with respect to the decline in lung function over a 5 year period.
Methods: In 2006/2007 we had repeatedly collected serum, BAL and sputum of 23 healthy smokers and 24
smokers with COPD (GOLD II) and analysed a panel of more than 100 different parameters. In 2012 we reinvited
these subjects to assess the change in lung function to enable the investigation of the potential prognostic value
of the 2006/2007 markers and to determine the long-term repeatability of selected blood and serum markers. In this
follow-up study we performed body-plethysmography, a blood gas analysis and collected blood and urine samples.
The change in lung function was compared with 67 markers from BAL, sputum, serum and whole blood that were
shown in the 2006/2007 assessment to be repeatable over a 6 week period.
Results: We were able to recruit 13 (54%) smokers with COPD and 11 (48%) former healthy smokers that
participated in the 2006/2007 study. The decline in lung function was larger in COPD smokers; five of them
changed to GOLD III, one to GOLD IV. Two healthy smokers changed to GOLD I. Blood cells, serum von Willebrand
factor and alpha-1-antitrypsin showed a good repeatability over 5 years. In COPD smokers a weak correlation
between 2006/2007 sputum markers of neutrophilic inflammation and the 5 year change in FEV1/FVC was found.
Conclusions: Our data suggests that inter-individual and group differences are maintained over a five year period.
Despite the large panel of markers available for this analysis, a potential prognostic value appears to exist only for
some sputum inflammatory markers. If these data can be confirmed in larger COPD cohorts, it would emphasize
the value of sputum markers in clinical trials and support the assumption that an anti-inflammatory treatment can
have long term benefits in COPD.
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In 2006/2007 we performed a large biomarker study, in
which we included two well matched groups of smokers,
one group with COPD (GOLD II) and one group with-
out [1]. Samples from all relevant compartments (spu-
tum, bronchoalveolar lavage (BAL), mucosal biopsies,
serum, whole blood, and urine) were collected twice
within a period of 6 weeks to assess the repeatability of
the large panel of markers. It was the aim to find robust
markers or combinations of markers which reflect the
underlying pathological processes in COPD and could
therefore be used as potential novel targets for treatment
and as markers in clinical trials with novel anti-
inflammatory compounds for COPD. In addition, we
wanted to know to what extent serum markers relate to
inflammatory markers within the airways to find more
easily accessible biomarkers for clinical trials.
The design of the 2006/2007 study was not suited to
provide information about the prognostic value of the
markers with respect to the long-term functional out-
come of patients with COPD. Markers with the potential
to serve as surrogate markers for lung function are
needed to enable shorter and therefore safer clinical tri-
als especially for novel anti-inflammatory compounds.
There is data available for serum markers for e.g. C-
reactive protein (CRP), fibrinogen and adiponectin with
respect to their predictive value on the decline of lung
function, exacerbation rate and mortality [2-6]. To our
knowledge, no prospective study exists with respect to
the predictive value of markers assessed in BAL and
sputum, except for a COPD study looking at predictors
in sputum for exacerbations induced by steroid with-
drawal [7]. As such comprehensive panels in different
compartments are generally not possible to be tested in
larger cohort studies; we considered it worth to address
this question despite the comparatively low number of
subjects available. In addition, we aimed to determine
the long-term repeatability of a number of blood and
serum biomarkers in this five year follow-up trial.
The data obtained from this re-evaluation could pro-
vide valuable information for large on-going or past
COPD trials like ECLIPSE [8] or SPIROMICS [9] for
which sputum data is available and were these prelimin-
ary findings could be validated.
Methods
Subjects
We invited all of the 47 participants of our initial bio-
marker study [1]. Thirteen (54%) smokers with COPD
and 11 (48%) former healthy smokers were recruited for
this follow-up study; the remaining subjects could not
be reached despite intensive recruitment efforts by
phone and mailing. Only one of the contacted subjects
declined to participate in the follow-up. The study wasconducted in accordance with Good Clinical Practice
and the Declaration of Helsinki. Subjects gave their writ-
ten informed consent. The study was approved by the
Ethical Committee of Hannover Medical School. The
same applies for the study conducted in Grosshansdorf,
which was approved by the Ethical Committee of the
Medical Chamber of Schleswig-Holstein. Data from a
subgroup of this cohort was used for comparison.
Study design
After providing informed consent, subjects underwent a
thorough physical examination and history assessment
of the past 5 years using a non-validated 10 question
questionnaire with analogue scales for information about
changes of different aspects in disease activity. Vital
signs, safety laboratory tests, blood gas analysis, 12-lead-
electrocardiogram, and body-plethysmography were also
performed. A blood sample was taken for the analysis of
selected serum markers and the current smoking status
was controlled by a urine cotinine measurement. The
low number of subjects available for the re-evaluation in
2012 did not ethically justify a repetition of the more in-
vasive procedures, but allowed to derive data for the
long term repeatability of blood and selected serum
markers.
Questionnaire
Subjects rated their estimation on a fixed scale from 1
(no) to 10 (yes). The following questions were asked (ab-
breviated): Did you experience (1) more cough over the
past 5 years? (2) more sputum? (3) a change in sputum
color? (4) more respiratory infections? (5) more days
with bad lung function? (6) Did your general health, or
(7) your exercise/activity capacity deteriorate over the
last 5 years? (8) Did your overall quality of life change
over the past 5 years?
Biomarker analysis
The analysis of leukotriene B4 (LTB4), Interleukin 6
(IL6), alpha-1-antitrypsin (A1AT), insulin growth factor
2 (IGF2) and von Willebrand Factor (VWF) was per-
formed by ELISA. We measured IGF2 and VWF in
stored serum samples of a well characterized independ-
ent COPD cohort [10] to test if we could reproduce
our findings. In addition, we tested leukocyte and
hematology parameters in this cohort as well as the
available serum/plasma markers (fibrinogen, CRP, leptin,
adeponectin, IL6) that were analyzed in 2006 for their
relationship to the lung function decline over three
years.
Statistical analysis
To assess the repeatability of the markers that were ana-
lysed both in 2006/2007 and in 2012 the correlation
Holz et al. BMC Pulmonary Medicine 2014, 14:30 Page 3 of 9
http://www.biomedcentral.com/1471-2466/14/30coefficient and the intra-class correlation coefficient was
computed. The intra-class correlation coefficients (ICC)
were derived from one-way ANOVA tables as the ratio of
variance among subjects to total variance based on 2 mea-
surements over the 5 year period ([11]: (BMS-WMS/2)/
((BMS-WMS/2) +WMS)); BMS = between group mean
square, WMS=within group mean square).
The change in lung function was taken as the major
clinical outcome variable. Due to the fact that 2006/2007
post-bronchodilator data was only available for the
COPD patients, we calculated the absolute change in
pre-bronchodilator FEV1 (L), the absolute change in
FEV1 (%pred.) and the absolute change in FEV1/FVC
(%). We consider this to be a valid approach, as
for COPD patients the pre- and post-bronchodilator
changes in FEV1 (L), FEV1 (%pred.) and FEV1/FVC were
significantly correlated (all r ≥ 0.92, ICC ≥ 0.92, p <
0.001). We correlated the changes in lung function only
with markers, which had acceptable repeatability in the
2 visits 2006/2007 (10 BAL-, 10 induced sputum -, 24
serum markers listed in Additional file 1: Table S2, plus
23 blood parameters, for which the repeatability was not
assessed). The analysis was performed for all subjects
and for both groups separately.Results
Subjects
Thirteen (54%) smokers with COPD and 11 (48%)
former healthy smokers could be recruited for this
follow-up study. Table 1 gives the 2006/2007 demo-
graphics for all subjects and for the re-evaluated sub-
group both for 2006/2007 and 2012. Additional file 1:
Table S1 provides information on medication, and co-
morbidities as derived from the medical history. TheTable 1 Demographics







Female/male 6/17 6/18 4/7
Age [years]a 54 (42, 65) 54 (46, 68) 56 (51
BMI [kg/m2] 25.4 ± 2.5 25.3 ± 3.4 25.5 ±
Pack-years & 34.0 (21.0) 48.0 (15.5)*** 32.0 (2
Cotinine (ng/mL) 1262 ± 722 1561 ± 968 1232 ±
FEV1 [L] 3.8 ± 0.8 2.0 ± 0.3*** 3.5 ±
FEV1 % pred. 112.5 ± 14.1 60.5 ± 6.8*** 114.9 ±
FVC [L] 5.1 ± 1.0 4.2 ± 0.9** 4.7 ±
FEV1/FVC [%] 75.4 ± 5.0 48.7 ± 7.4*** 74.3 ±
pO2 [mm Hg] 82.9 ± 9.7 73.3 ± 5.3*** 81.2 ±
In 2012: COPD smokers: 2 quit smoking, 2 reduced smoking; healthy smokers: 2 qu
a:presented as mean (minimum, maximum), all other data is presented as mean ± Smedian (interquartile range, IQR) time between visits
was 5.0 (4.7, 5.2) years.
Changes in lung function over a 5 year period
With respect to the demographic data (Table 1), neither
the healthy smokers nor the smokers with COPD that
could be recruited for this follow-up investigation, dif-
fered from the groups studied in 2006/2007. In both
groups two subjects stopped smoking, but a significant
correlation for urine cotinine between 2006/2007 and
2012 indicates that no major changes in smoking behav-
ior occurred (r = 0.79, p < 0.001).
Both groups showed a significant decline in lung function
(pre-bronchodilator) over the five year period, which was
more pronounced in smokers with COPD (Figure 1).
The median (IQR) change in pre-bronchodilator FEV1
was −0.57 (0.49) L and −0.35 (0.37) L in smokers with and
without COPD, respectively (both p < 0.005, Wilcoxon test).
The absolute decline in pre-bronchodilator FEV1 %pred.
was −16.1 (15.8) and −5.4 (10.0) % (p < 0.01, p < 0.05), and
the absolute decline in pre-bronchodilator FEV1/FVC
was −5.6 (13.4) and −2.6 (6.3) % (p < 0.05, p = 0.09), respect-
ively. Five smokers with COPD changed to GOLD III, one
to GOLD IV. Two former healthy smokers changed to
GOLD I (FEV1/FVC post-bronchodilator < 70%). The re-
sults of the questionnaire were compatible with this obser-
vation, showing significantly higher levels on the analog
scales for questions related to general health, cough, exer-
cise tolerance, general lung health, and quality of life.
Repeatability of whole blood parameters over a 5 year
period
Among the cellular blood parameters that were analyzed
at both time points (Table 2), there was only a slight de-












, 61) 53 (50, 56) 60 (56, 66) 58 (55, 61)
1.8 24.4 ± 3.0 26.7 ± 3.0 25.5 ± 3.9
1.0) 47.0 (15.0) 37.5 (16.8) 50.1 (16.7)
548 1620 ± 748 867 ± 659 1585 ± 678
0.6 2.0 ± 0.3 3.2 ± 0.5 1.5 ± 0.5
12.8 60.7 ± 5.5 109,6 ± 14.2 47.3 ± 15.0
0.9 4.3 ± 0.8 4.5 ± 0.7 3.6 ± 0.8
5.1 48.2 ± 6.7 71.1 ± 4.2 41.0 ±11.7
9.2 75.1 ± 5.7 76.5 ± 7.4 69,2 ± 7.6
it smoking, 1 reduced smoking.
D, ** = p < 0.01, *** = p < 0.005 & median (IQR).
Figure 1 Change in pre-bronchodilator FEV1 (L), FEV1 (% pred.) and FEV1/FVC (left, middle, right) from 2006/2007 to 2012 in smokers
with COPD (circles) and former healthy smokers (open squares). A larger drop below the line of identity indicates a larger decline in the
respective lung function level. The changes with respect to GOLD category as listed in the text were done using post-bronchodilator values,
which are slightly higher as compared to the pre-bronchodilator values displayed in this figure.
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corpuscular hemoglobin (MCH) levels in both groups,
with more pronounced increases in smokers with COPD
(p < 0.005). Table 2 gives the correlation and the ICCs
for markers that were analyzed both in 2006/2007 and
2012. Additional file 2: Figure S1 shows the correlation
between time points for blood leukocytes and the per-
centage of blood monocytes. In line with the 2006/2007
data, we found significantly higher serum levels for
A1AT, IL6 and VWF in smokers with COPD, while the
observed difference between groups for LTB4 could not
be reproduced. Levels were remarkably stable for serum
VWF (Figure 2). Interestingly, the 2 healthy smokers
that progressed to COPD GOLD 1 had the highest con-
trol group levels of A1AT and IL6 in 2012.
Relationship between markers analyzed in 2006/2007 and
the 5 year decline in lung function
Additional file 1: Table S2 lists all those parameters with
acceptable repeatability in 2006/2007 (ICC > 0.6) in
smokers with and without COPD. For a full list of
markers that were assessed in 2006/2007 refer to
Roepcke et al. [1]. For all markers listed in Table 3 as
well as for whole blood markers and hematology data
we analyzed the relationship to the decline in pre-
bronchodilator FEV1 (L), FEV1 (%pred.) and the change
in the FEV1/FVC ratio. Table 3 provides a list for all
markers, which showed a significant correlation coeffi-
cient >0.50. All these correlations were checked visually
to control for a bias due to outliers.
In 2006/2007 we also computed cumulative scores
based on different BAL or sputum markers [1]. No rela-
tionship was detected between lung function changes
and the computed BAL score. For the sputum cumula-
tive score (based on the levels of A1AT, IL6, MMP7,
HSA and sputum neutrophils), which showed a betterrepeatability over 6 weeks as compared to sputum neu-
trophils alone [1], we found a correlation with the de-
cline in FEV1 (L) and FEV1 (% pred) (r = −0.78, p = 0.02;
r = −0.80, p = 0.02) in former healthy smokers. However,
only 8 subjects were available for this comparison.
Higher levels of BAL or induced sputum markers asso-
ciated with neutrophilic airway inflammation (e.g. IL8,
calprotection or matrix metalloproteases, MMPs) in
2006/2007 were associated with a larger decline in lung
function over a 5 years period. For serum leptin and
IGF2 a reverse relationship was found, showing that a
stronger decline in lung function was related to lower
levels in serum. Due to the fact that these observations
were limited to subgroups and are based on small sub-
ject numbers the data needs to be interpreted with
caution.Testing results in an independent COPD cohort
Due to the finding that serum IGF2 might be playing a
protective role with respect to the decline in lung func-
tion we aimed to test this preliminary result in an inde-
pendent well characterized group of smoking COPD
GOLD 2 patients [10], for which 3 year follow-up data
was available (Grosshansdorf cohort). Demographic data
of this cohort is presented in Additional file 1: Table S3.
The Grosshansdorf cohort does not include healthy
smokers, therefore no re-evaluation of differences be-
tween groups could be performed. The 24 patients were
on average about 10 years older, had a higher BMI (~3),
and more pack-years. The median (IQR) change in FEV1
was −0.18 (0.24) L (p < 0.001, Wilcoxon Test). The de-
cline in FEV1 (% pred.) was −3.5 (8.4) % (p < 0.0065) and
the change in FEV1/FVC was 1.1 (8.3) %. Four of the
GOLD 2 smokers progressed to GOLD 3 over the three
year period. There was a comparable good repeatability
Table 2 Repeatability of hematology data and selected serum proteins
Parameter Unit r ICC Healthy smokers COPD smokers Healthy vs. COPD 2006/2007 vs. 2012$
2006/2007# 2012& All Healthy COPD
smokers smokers
Whole blood Leukocytes 109/L 0.84 0.85 7.1 (4.8-7.9) 7.4 (6.8-9.3)
Neutrophils (%) 0.54 0.50 54.3 (51.4-63.8) 62.6 (58.4-64.4)
Monocytes (%) 0.72 0.70 8.4 (8.2-9.0) 7.7 (6.9-9.4) p = 0.03
Erythrocytes 1012/L 0.79 0.78 4.8 (4.6-5.0) 4.8 (4.5-5.0)
Thrombocytes 109/L 0.86 0.86 248.0 (208.0-272.0) 208.0 (176.0-257.0)
Anisocytosis 0.81 0.82 45.0 (43.0-47.0) 46.0 (46.0-47.0) p = 0.014
Hemoglobin g/dL 0.80 0.81 14.8 (14.0-15.1) 15.0 (14.2-15.7)
Hematocrit % 0.73 0.73 44.0 (42.0-44.0) 44.0 (43.0-47.0)
MCH pg 0.83 0.68 30.8 (29.2-31.9) 31.5 (30.7-32.6) p < 0.001 p = 0.03 p < 0.005
MCV 109 μL 0.91 0.91 89.1 (87.0-94.8) 93.0 (91.1-94.4) p = 0.008
Serum Serum creatinine mg/dL 0.88 0.71 0.9 (0.8-1.0) 0.8 (0.7-0.9) p = 0.006 p = 0.003
ALP U/L 0.86 0.78 79.0 (65.0-95.0) 89.0 (70.5-97.5)
AST/GOT U/L 0.68 0.79 25.0 (24.0-30.0) 23.5 (20.5-29.5)
ALT/GPT U/L 0.67 0.58 23.0 (21.0-38.0) 21.5 (18.5-33.5)
G-GT U/L 0.87 0.82 27.0 (20.0-30.0) 42.5 (22.0-56.0) p = 0.09 p = 0.05 p = 0.01 p = 0.03
LTB4 μg/mL 0.01 −0.02 1.5 (0.9-2.1) 1.6 (1.2-2.0) m: p = 0.0051 nd nd nd
A1AT ng/mL 0.74 −0.53 767.9 (707.5-844.5) 870.9 (828.8-906.6) m: p = 0.014 p = 0.02 nd nd nd
IL6 pg/mL 0.25 −0.34 1.6 (1.1-3.4) 3.2 (2.0-4.0) p = 0.002 p = 0.02 nd nd nd
VWF U/mL 0.69 0.67 1.3 (1.1-1.6) 1.8 (1.6-2.0) p = 0.003 p = 0.004
MCH: mean corpuscular/cellular hemoglobin. MCV: mean corpuscular/cell volume, ALT/GPT:Alanin-Aminotransferase/Glutamat-Pyruvat-Transaminase.
AST/GOT: Aspartat-Aminotransferase/Glutamat-Oxalacetat-Transaminase, ALP: Alkaline phosphatase, GGT: Gamma-glutamyltransferase.
#Roepcke et al. PLOS One 2012 [1] Table 4/Table S8. m =male subjects, & Mann–Whitney-U-test, $ Wilcoxon-test.
r = correlation coeficient. ICC = intraclass correlation coeficient comparing 2006/2007 and 2012 data of all subjects.





















Figure 2 A significant difference between smokers with and without COPD for the level of serum VWF was shown in 2006/2007 and
this difference was maintained in 2012 (left). The correlation between 2006/2007 and 2012 levels of VWF was significant (right). The data is
shown for smokers with (circles) and without (open squares) COPD and with the line of identity.
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file 1: Table S4).
In these 24 COPD GOLD 2 patients, we measured
IGF2 and VWF in stored serum samples, but we could
not reproduce the findings in our GOLD 2 patient
group. In addition, we did not find a relationship to
the lung function decline over three years (exceeding
r =0.50) with respect to leukocyte or hematology param-
eters or available serum/plasma markers (fibrinogen,
CRP, leptin, adeponectin, IL6) that were analyzed in this
cohort in 2006.
Discussion
Despite the available large panel of markers from BAL,
sputum, serum and blood, evidence for a potential prog-
nostic value was found only for some sputum inflamma-
tory markers. Naturally only low numbers of subjects
are available in studies involving invasive procedures like
our initial trial in 2006/2007. Therefore, the association
of these markers with the decline in lung function has to
be interpreted with caution. This is also reflected by the
fact, that our interesting observation, that COPD pa-
tients with higher serum levels of leptin and IGF2
showed a smaller decline in lung function could not be
reproduced in an independent group of COPD patients.
For most hematology parameters, however, inter-
individual and group differences were shown to be stable
over a five year period. This was also true for the
serum concentration of alpha-1-antitrypsin and von
Willebrand-Factor.
The lung function decline was larger in smoking
COPD patients than in former healthy smokers. The an-
nual decline in these smokers exceeded the average
amount reported in the UPLIFT study, the Hokkaido
COPD cohort or the study by Higashimoto et al.[2,12,13]. These cohorts, however, only included 20-30%
active smokers. The annual decline in lung function of
the GOLD 2 COPD smokers from the Grosshansdorf
cohort was comparable [10] and larger declines in FEV1
were also reported for active smokers with COPD in the
ECLIPSE cohort [14]. Although the rate of individual an-
nual decline in FEV1 was based on only two measure-
ments several years apart, which could be considered as
a limitation of our study, the overall magnitude of the
decline rate was in agreement with other studies on ac-
tively smoking COPD patients.
While the level of sputum neutrophils in 2006/2007
was not related to the change in lung function parame-
ters over the investigated 5 years period, we found
several markers associated with neutrophilic airway in-
flammation in the lung, like sputum IL8, BAL calprotec-
tion or sputum MMPs, for which the concentrations in
2006/2007 correlated with a larger decline in lung func-
tion. Interestingly, 4 of the 5 sputum markers we choose
in the initial analysis [1] to define an inflammatory
phenotype to cover more aspects of inflammation than
neutrophils alone, were among the markers that showed
significant correlations with the lung function decline.
Also the inflammatory score itself was significant, how-
ever, only available for 8 subjects. Overall the evidence
was weak and higher correlation coefficients with lung
function decline were found only in subgroups. In
addition, the multiple testings have to be considered and
therefore this data needs to be interpreted with caution.
Blood haematology markers have moved into the focus
of biomarker studies. In the SPIROMICS initiative (Sub-
populations and intermediate outcome measures in
COPD study) blood cell counts and haematology vari-
ables were assessed and shown to be related to COPD
severity [15]. Our data suggests that inter-individual
Table 3 Correlation between markers assessed 2006/2007 and the decline in lung function
FEV1 (L) FEV1 (%pred.) FEV1/FVC (%)












IGF2 0.74*** 0.72** 0.78***








Only significant correlations are displayed and are either p < 0.05, or as marked: *p < 0.02, **p ≤ 0.01, ***p ≤ 0.005.
BAL = bronchial alveolar lavage, IS = induced sputum, Calprot. = Calprotectin, HSA = human serum albumin, HCT = hematocrit, HGB = hemoglobin, MMP =matrix
metalloproteinase, RBC = red blood cells, ALP: Alkaline phosphatase. A negative correlation means that a stronger decline in lung function over the 5 year period
is associated with higher levels of the respective parameter (e.g. sputum MMP7). A positive correlation indicates that lower levels of the respective parameter are
associated with a stronger decline in lung function (e.g. IGF2).
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out COPD persist over a five year period and that these
markers show a good repeatability. In 2006/2007 we
found differences in anisocytosis, an indicator for an-
aemia and the mean corpuscular volume (MCV) be-
tween healthy smokers and smoking COPD patients. In
line with these findings, SPIRIOMICS reported increased
levels of haemoglobin, haematocrit, MCV and leukocyte
counts in COPD patients [15]. The observed relationship
with lung function in healthy smokers of these haema-
tology markers suggests that it might be worth to re-
evaluate these markers in already available data of large
COPD cohorts.
A good repeatability was also found for serum A1AT
and VWF and the differences in serum concentrations of
A1AT, VWF and IL6 between groups were still detect-
able, despite lower numbers of subjects available. This
confirms that these markers play a role in COPD patho-
genesis, but do not appear to have any prognostic value.
A positive correlation with the lung function decline
was found for IGF2 and leptin, suggesting a potential
protective role. For leptin this could not be observed in
the independent Grosshansdorf COPD GOLD 2 cohort.As no IGF2 data was available for this group, we ana-
lysed IGF2 from stored blood samples of 2006. The
levels were comparable to the levels detected in fresh
samples 2012, suggesting that storage did not have a
negative impact. Nevertheless, we failed to find a com-
parable relationship of this marker with the lung func-
tion decline.
Our negative findings with respect to the large panel
of serum markers we analysed in 2006/2007 is in line
with data from the much larger Hokkaido COPD cohort,
where only adiponectin (of 52 plasma markers) was re-
ported to relate to the lung function decline over 5 years
[5,13]. In the ECLIPSE study a similar analysis was per-
formed in almost 1800 patients with 7 serum markers
[14]. Although significant, only a small effect for CC16
was found; CC16 being responsible for a 4 ml FEV1 de-
cline/year. Using basically the same dataset from the
ECLIPSE study Agusti et al. reported that those COPD
subjects with persistently high levels of systemic inflam-
matory markers had a higher incidence of exacerbations
and a higher rate of mortality [16]. In addition it was
shown in ECLIPSE that considering serum levels of
IL6 improves the predictive value of age, BODE and
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been published for the follow up of COPD patients from
the Copenhagen City Heart – (2 years) and General
Population Study (5 years), were patients with high
levels of CRP, fibrinogen and leukocyte count were
shown to have a higher risk of exacerbations [18]. Serum
CCL-18 levels were also found to be related to mortality
in the ECLIPSE cohort [19]. There is quite a large num-
ber of plasma markers that was found to be associated
with the exacerbation rate in COPD [20]. A comprehen-
sive table which lists the evidence for 17 potential
biomarkers with the respective outcomes can be found
in the paper by Sin and Vestbo [21] and Koutsokera
et al. [3].Conclusion
In summary, our study provides data about the long
term repeatability of selected blood and serum markers
and suggests that in current smokers with COPD there
is relationship between sputum markers associated with
markers of neutrophilic inflammation and lung function
decline. The data could provide valuable information for
large on-going or past COPD trials like ECLIPSE or
SPIROMICS for which sputum data is available and
where these preliminary findings could be validated.Additional files
Additional file 1: Table S1. Medication of COPD patients between
2006/2007 and 2012. Table S2. List of all markers, which were shown to
be repeatable in 2006/2007. Table S3. Demographic data of an
independent group of smoking COPD GOLD 2 patients from
Grosshansdorf, Germany. Table S4. Repeatability of blood cells and
hematology markers between 2006 and 2009.
Additional file 2: Figure S1. Correlation for total blood leukocytes (left)
and the percentage of monocytes (right) between 2006/2007 and 2012.
Open symbols: smokers without COPD, closed symbols smokers with
COPD.
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